Tradestie Institutional Equity Comparison Engine

INCY vs IONS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

INCY Overall Edge

INCY Captures Institutional Edge (3โ€“1 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Incyte Genomics Inc (INCY) driven by superior Valuation, Growth & Margin, Momentum & Technical while IONS counters with relative strength in Options & Structure. Fundamentally, INCY trades at 14.0x Forward P/E with 32.2% operating margin (+14.0% YoY revenue) versus IONS at 90.9x Forward P/E and -58.8% operating margin (+54.9% YoY). In options structure, INCY sits in CONSOLIDATION (64th %ile IV; Dealer Gamma Walls on Pro) against IONS sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner INCY
INCY 14.0x vs IONS 90.9x Fwd P/E
Growth & Margin Winner INCY
Op Margin 32.2% vs -58.8% ยท YoY +14.0% vs +54.9%
Momentum & Technical Winner INCY
1Y +13.7% vs -59.1% ยท 52W Pos 71% vs 2%
Options & Structure Winner IONS
CONSOLIDATION (64th %ile IV) vs BREAKDOWN (17th %ile IV)
INCY NASDAQ
Incyte Genomics Inc
Services-Commercial Physical & Biological Research
$119.86
-0.92% 1D
Market Cap $24.8B
1M Return +6.01%
1Y Return +13.71%
Forward P/E 14.0x
Unified AI Score
61.2 / 100 BUY
Tech 45.0 Fund 56.0 Flow 68.0 Mom 60.0
IONS NASDAQ
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
1M Return -33.48%
1Y Return -59.1%
Forward P/E 90.9x
Unified AI Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: INCY +13.71% IONS -59.1% Spread: +72.81 pp (INCY Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period INCY Revenue IONS Revenue INCY Op. Margin IONS Op. Margin Margin Edge
FY2018 $1.88B $600M 6.9% -10.2% INCY
FY2019 $2.16B $1.12B 18.6% 32.6% IONS
FY2020 $2.67B $730M -9.9% -23.6% INCY
FY2021 $2.99B $810M 19.6% -3.7% INCY
FY2022 $3.39B $590M 17.1% -69.8% INCY
FY2023 $3.70B $790M 16.8% -44.9% INCY
FY2024 $4.24B $710M 1.4% -67.4% INCY
FY2025 $5.14B $940M 29.5% -40.4% INCY

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: INCY (8) vs IONS (2)
Institutional Metric INCY IONS Criterion Row Winner
Market Capitalization Scale $24.8B $4.7B Larger Scale INCY
Trailing P/E Ratio Valuation 62.1x 90.9x Lower Multiple INCY
Forward P/E Ratio Valuation 14.0x 90.9x Lower Multiple INCY
Revenue Growth (YoY) Growth +14.0% +54.9% Higher Growth IONS
Operating Margin (TTM) Profitability 32.2% -58.8% Higher Margin INCY
Net Profit Margin Profitability 6.7% -56.9% Higher Margin INCY
Return on Equity (ROE) Capital Efficiency 7.8% -108.0% Higher ROE INCY
52-Week Range Position Momentum 71% ($89โ€“$133) 2% ($27โ€“$87) Stronger Trend INCY
Beta / 30D Volatility Risk Regime 0.30ฮฒ ยท 35% Vol 0.18ฮฒ ยท 86% Vol Lower Realized Risk INCY
Unified Institutional Score Composite Signal 61.2 / 100 (BUY) 63.9 / 100 (BUY) Higher Composite IONS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full INCY vs IONS Buy Guide
INCY CONSOLIDATION
78d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 64th %ile
IV Regime Elevated (60thโ€“80th %ile)
Live INCY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
IONS BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 17th %ile
IV Regime Compressed (<25th %ile)
Live IONS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither INCY nor IONS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.